Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Innate licenses AZ's Lumoxiti

Executive Summary

Innate Pharma SA licensed US and EU rights to AstraZeneca PLC’s Lumoxiti (moxetumomab pasudotox), which was recently approved by the FDA to treat hairy cell leukemia (HCL). The deal strengthens a three-year-old relationship between the partners.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register